Skip to Main Content
Skip Nav Destination

Rare Germline CTR9 Variants Enhance the Risk of Myeloid Malignancy

February 1, 2024

Major Finding: A rare variant association analysis reveals that partial CTR9 loss increases myeloid malignancy risk.

Concept: Partial CTR9 loss enhances super elongation complex activity and hematopoietic stem cell self-renewal.

Impact: This study implies that modulating transcription elongation may be a strategy to prevent blood cancers.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal